Skip to main content

CORRECTION article

Front. Mol. Neurosci., 29 October 2020
Sec. Molecular Signalling and Pathways

Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity

\nDi-Sheng Lu&#x;Di-Sheng LuCe Chen&#x;Ce ChenYa-Xin Zheng&#x;Ya-Xin ZhengDai-Di LiDai-Di LiGuo-Qing WangGuo-Qing WangJie LiuJie LiuJingshan ShiJingshan ShiFeng Zhang
Feng Zhang*
  • Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China

A Corrigendum on
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity

by Lu, D.-S., Chen, C., Zheng, Y.-X., Li, D.-D., Wang, G.-Q., Liu, J., et al. (2018). Front. Mol. Neurosci. 11:155. doi: 10.3389/fnmol.2018.00155

In the original article, there was a mistake in Figure 6 as published. One western blot band of β-actin corresponding to TNF-α protein level 21 days after daily L-DOPA combined with ICA treatment in Figure 6B was inserted incorrectly. The corrected Figure 6 appears below.

FIGURE 6
www.frontiersin.org

Figure 6. ICA inhibited the neuroinflammation in LID after 6-OHDA-induced DA neuronal damage. The protein levels of neuroinflammatory factors, such as COX-2, IL-1β and TNF-α, in the SN were detected 7 (A) and 21 (B) days after daily L-DOPA (25 mg/kg, i.p.) combined with ICA (20 mg/kg, p.o.) treatment by western blotting. Data were shown as mean ± SEM from six rats (n = 6). *p <0.05 compared with the control group; #p <0.05 compared with 6-OHDA-treated group; Ψp <0.05 compared with 6-OHDA+L-DOPA group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Parkinson's disease, L-DOPA, dyskinesia, Icariin, combination treatment

Citation: Lu D-S, Chen C, Zheng Y-X, Li D-D, Wang G-Q, Liu J, Shi J and Zhang F (2020) Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity. Front. Mol. Neurosci. 13:605722. doi: 10.3389/fnmol.2020.605722

Received: 13 September 2020; Accepted: 30 September 2020;
Published: 29 October 2020.

Edited and reviewed by: Jean-Marc Taymans, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Copyright © 2020 Lu, Chen, Zheng, Li, Wang, Liu, Shi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Feng Zhang, zhangfengzmc@163.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.